Holen Sie sich die Stockscreener-App
2.97
4.21%
0.12
Handel nachbörslich:
2.86
-0.11
-3.70%
Schlusskurs vom Vortag:
$2.85
Offen:
$2.85
24-Stunden-Volumen:
223.05K
Relative Volume:
0.36
Marktkapitalisierung:
$44.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.4802
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
+2.41%
1M Leistung:
-15.38%
6M Leistung:
-52.10%
1J Leistung:
-84.24%
1-Tages-Spanne:
$2.8108
$3.03
1-Wochen-Bereich:
$2.45
$3.03
52-Wochen-Spanne:
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.97 | 39.51M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - WV News
Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛
Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest
Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Why is Jasper Therapeutics Inc. Equity Warrant stock attracting strong analyst attentionMaximize portfolio value with smart investment plans - Jammu Links News
How does Jasper Therapeutics Inc. compare to its industry peersFree Stock Forecasts For 2025 - jammulinksnews.com
What institutional investors are buying Jasper Therapeutics Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
When is Jasper Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - Jammu Links News
Does Jasper Therapeutics Inc. Equity Warrant stock perform well during market downturnsMassive wealth growth - Jammu Links News
How strong is Jasper Therapeutics Inc. Equity Warrant company’s balance sheetGain access to exclusive stock analysis - Jammu Links News
Is Jasper Therapeutics Inc. Equity Warrant stock overvalued or undervaluedFree Stock Market Return Analysis - jammulinksnews.com
What is the dividend policy of Jasper Therapeutics Inc. stockMaximize gains with professional stock picks - Jammu Links News
Today is July 27 2025 - AInvest
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
When is the best time to buy Jasper Therapeutics Inc. Equity Warrant stockConsistently high yield - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockFree Stock Market Forecast Reports - Autocar Professional
What drives Jasper Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Is Jasper Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):